Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314123 | 0.98 | TSHR (0.38) | TSHRLTA4HALDH1A1MAPTTHRB | |
| Bicarbonate SCHEMBL5555311 | 0.89 | HRH3 (0.38) | TSHRALDH1A1MAPTTHRBLMNA | |
| SCHEMBL2494566 | 0.86 | TSHR (0.44) | TSHRLTA4HALDH1A1MAPTTHRB | |
| SCHEMBL3303147 | 0.84 | TSHR (0.47) | TSHRLTA4HALDH1A1MAPTTHRB | |
| SCHEMBL3308645 | 0.84 | LTA4H (0.47) | TSHRLTA4HALDH1A1MAPTTHRB | |
| SCHEMBL3307520 | 0.82 | LTA4H (0.46) | TSHRLTA4HALDH1A1MAPTTHRB | |
| SCHEMBL5935796 | 0.82 | LTA4H (0.50) | TSHRLTA4HALDH1A1MAPTTHRB | |
| SCHEMBL23868239 | 0.81 | NPC1 (0.37) | LTA4HALDH1A1THRBKDM4EHRH3 | |
| SCHEMBL6690746 | 0.81 | LTA4H (0.49) | TSHRLTA4HALDH1A1MAPTTHRB | |
| SCHEMBL5935795 | 0.81 | LTA4H (0.49) | TSHRLTA4HALDH1A1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-27 | — | — | US | disclosed |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| EP-2072496-B1 | METHOD FOR PRODUCING HIGH-PURITY QUATERNARY AMMONIUM SALT | OTSUKA CHEMICAL CO LTD (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-2958181-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9653754-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9620814-B2 | — | — | 2017-04-11 | — | — | US | disclosed |
| US-9515348-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-06-23 | — | — | US | disclosed |
| US-20120308881-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQEUOUS-ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120264010-A1 | NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-10-18 | — | — | US | disclosed |
| US-8029690-B2 | Process for production of highly pure quaternary ammonium salt | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8029689-B2 | Method for producing high-purity quaternary ammonium salt | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100099031-A1 | NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2166611-A1 | NONAQUEOUS ELECTROLYTE, AND RECHARGEABLE BATTERY WITH THE NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-20100044617-A1 | Method for producing high-purity quaternary ammonium salt | STELLA CHEMIFA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090272933-A1 | Process for production of highly pure quaternary ammonium salt | STELLA CHEMIFA CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2098518-A1 | PROCESS FOR PRODUCTION OF HIGHLY PURE QUATERNARY AMMONIUM SALT | Otsuka Chemical Co., Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-2072496-A1 | METHOD FOR PRODUCING HIGH-PURITY QUATERNARY AMMONIUM SALT | Otsuka Chemical Co., Ltd. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | TSHR 339/4885LTA4H 153/4885ALDH1A1 784/4885 |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | TSHR 339/4885LTA4H 153/4885ALDH1A1 784/4885 |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | TSHR 327/4885LTA4H 139/4885ALDH1A1 794/4885 |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | TSHR 340/4885LTA4H 160/4885ALDH1A1 763/4885 |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | PTGER1, LTB4R2, LTB4R | TSHR 407/4885LTA4H 126/4885ALDH1A1 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.